Northwest Biotherapeutics, Inc. (NWBO)
USD 0.21
(-1.87%)
USD 0.21
(-1.87%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 74.92 Million USD | -53.01% |
| 2022 | 159.42 Million USD | -2.88% |
| 2021 | 164.15 Million USD | -58.53% |
| 2020 | 395.84 Million USD | 651.19% |
| 2019 | 52.69 Million USD | -26.63% |
| 2018 | 71.82 Million USD | -25.34% |
| 2017 | 96.2 Million USD | 21.15% |
| 2016 | 79.4 Million USD | 5.21% |
| 2015 | 75.47 Million USD | -19.25% |
| 2014 | 93.46 Million USD | 226.79% |
| 2013 | 28.6 Million USD | 20.97% |
| 2012 | 23.64 Million USD | -54.87% |
| 2011 | 52.38 Million USD | 87.24% |
| 2010 | 27.97 Million USD | 34.58% |
| 2009 | 20.78 Million USD | 50.86% |
| 2008 | 13.78 Million USD | 375.34% |
| 2007 | 2.89 Million USD | -55.08% |
| 2006 | 6.45 Million USD | -46.44% |
| 2005 | 12.04 Million USD | 108.64% |
| 2004 | 5.77 Million USD | 575.44% |
| 2003 | 855 Thousand USD | -68.29% |
| 2002 | 2.69 Million USD | 6.08% |
| 2001 | 2.54 Million USD | -59.06% |
| 2000 | 6.2 Million USD | -22.09% |
| 1999 | 7.96 Million USD | 0.0% |
| 1998 | - USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 82.03 Million USD | 9.5% |
| 2024 Q2 | 85.96 Million USD | 4.79% |
| 2023 Q1 | 88.84 Million USD | -44.27% |
| 2023 Q3 | 96.61 Million USD | 7.98% |
| 2023 Q2 | 89.47 Million USD | 0.7% |
| 2023 Q4 | 74.92 Million USD | -22.45% |
| 2023 FY | 74.92 Million USD | -53.01% |
| 2022 Q4 | 159.42 Million USD | 13.92% |
| 2022 Q3 | 139.94 Million USD | 17.42% |
| 2022 Q1 | 151.18 Million USD | -7.9% |
| 2022 FY | 159.42 Million USD | -2.88% |
| 2022 Q2 | 119.18 Million USD | -21.16% |
| 2021 FY | 164.15 Million USD | -58.53% |
| 2021 Q1 | 385.66 Million USD | -2.57% |
| 2021 Q3 | 329.95 Million USD | -12.85% |
| 2021 Q2 | 378.6 Million USD | -1.83% |
| 2021 Q4 | 164.15 Million USD | -50.25% |
| 2020 Q4 | 395.84 Million USD | 65.18% |
| 2020 FY | 395.84 Million USD | 651.19% |
| 2020 Q3 | 239.64 Million USD | 149.05% |
| 2020 Q2 | 96.22 Million USD | 117.82% |
| 2020 Q1 | 44.17 Million USD | -16.17% |
| 2019 Q2 | 67.71 Million USD | -18.39% |
| 2019 Q1 | 82.96 Million USD | 15.51% |
| 2019 FY | 52.69 Million USD | -26.63% |
| 2019 Q4 | 52.69 Million USD | -18.53% |
| 2019 Q3 | 64.68 Million USD | -4.48% |
| 2018 Q4 | 71.82 Million USD | -23.16% |
| 2018 FY | 71.82 Million USD | -25.34% |
| 2018 Q1 | 112.8 Million USD | 17.26% |
| 2018 Q2 | 112.26 Million USD | -0.48% |
| 2018 Q3 | 93.47 Million USD | -16.74% |
| 2017 Q2 | 82.62 Million USD | -2.74% |
| 2017 Q1 | 84.95 Million USD | 6.99% |
| 2017 FY | 96.2 Million USD | 21.15% |
| 2017 Q4 | 96.2 Million USD | 3.91% |
| 2017 Q3 | 92.58 Million USD | 12.05% |
| 2016 Q2 | 70.58 Million USD | 3.16% |
| 2016 Q1 | 68.41 Million USD | -9.35% |
| 2016 Q3 | 53.96 Million USD | -23.54% |
| 2016 FY | 79.4 Million USD | 5.21% |
| 2016 Q4 | 79.4 Million USD | 47.14% |
| 2015 Q1 | 120.11 Million USD | 28.51% |
| 2015 Q3 | 108.99 Million USD | -22.38% |
| 2015 Q2 | 140.41 Million USD | 16.91% |
| 2015 Q4 | 75.47 Million USD | -30.76% |
| 2015 FY | 75.47 Million USD | -19.25% |
| 2014 Q4 | 93.46 Million USD | 54.2% |
| 2014 Q3 | 60.61 Million USD | 42.8% |
| 2014 Q2 | 42.44 Million USD | -2.58% |
| 2014 Q1 | 43.57 Million USD | 52.34% |
| 2014 FY | 93.46 Million USD | 226.79% |
| 2013 FY | 28.6 Million USD | 20.97% |
| 2013 Q3 | 32.71 Million USD | 10.2% |
| 2013 Q1 | 28.57 Million USD | 20.85% |
| 2013 Q2 | 29.69 Million USD | 3.92% |
| 2013 Q4 | 28.6 Million USD | -12.58% |
| 2012 Q4 | 23.64 Million USD | -38.64% |
| 2012 Q2 | 31.67 Million USD | 26.48% |
| 2012 FY | 23.64 Million USD | -54.87% |
| 2012 Q1 | 25.04 Million USD | -52.19% |
| 2012 Q3 | 38.53 Million USD | 21.64% |
| 2011 Q1 | 34.94 Million USD | 24.91% |
| 2011 FY | 52.38 Million USD | 87.24% |
| 2011 Q4 | 52.38 Million USD | 9.04% |
| 2011 Q3 | 48.04 Million USD | -7.57% |
| 2011 Q2 | 51.97 Million USD | 48.72% |
| 2010 Q1 | 21.25 Million USD | 2.23% |
| 2010 Q2 | 21.58 Million USD | 1.58% |
| 2010 Q3 | 23.22 Million USD | 7.58% |
| 2010 Q4 | 27.97 Million USD | 20.48% |
| 2010 FY | 27.97 Million USD | 34.58% |
| 2009 Q4 | 20.78 Million USD | 12.67% |
| 2009 FY | 20.78 Million USD | 50.86% |
| 2009 Q2 | 18.93 Million USD | 10.66% |
| 2009 Q3 | 18.45 Million USD | -2.54% |
| 2009 Q1 | 17.1 Million USD | 24.16% |
| 2008 Q2 | 6.53 Million USD | 188.22% |
| 2008 FY | 13.78 Million USD | 375.34% |
| 2008 Q4 | 13.78 Million USD | 30.57% |
| 2008 Q3 | 10.55 Million USD | 61.52% |
| 2008 Q1 | 2.26 Million USD | -21.8% |
| 2007 FY | 2.89 Million USD | -55.08% |
| 2007 Q1 | 8.23 Million USD | 27.6% |
| 2007 Q2 | 10.77 Million USD | 30.81% |
| 2007 Q3 | 6.76 Million USD | -37.23% |
| 2007 Q4 | 2.89 Million USD | -57.12% |
| 2006 Q2 | 4.81 Million USD | -78.17% |
| 2006 Q3 | 4.77 Million USD | -0.93% |
| 2006 Q4 | 6.45 Million USD | 35.28% |
| 2006 FY | 6.45 Million USD | -46.44% |
| 2006 Q1 | 22.05 Million USD | 83.04% |
| 2005 FY | 12.04 Million USD | 108.64% |
| 2005 Q1 | 6.82 Million USD | 18.13% |
| 2005 Q4 | 12.04 Million USD | 20.35% |
| 2005 Q2 | 8.11 Million USD | 18.88% |
| 2005 Q3 | 10.01 Million USD | 23.45% |
| 2004 FY | 5.77 Million USD | 575.44% |
| 2004 Q4 | 5.77 Million USD | 12.7% |
| 2004 Q3 | 5.12 Million USD | 250.48% |
| 2004 Q1 | 1.4 Million USD | 63.86% |
| 2004 Q2 | 1.46 Million USD | 4.35% |
| 2003 Q4 | 855 Thousand USD | -1.84% |
| 2003 Q2 | 802 Thousand USD | -55.76% |
| 2003 Q3 | 871 Thousand USD | 8.6% |
| 2003 Q1 | 1.81 Million USD | -32.75% |
| 2003 FY | 855 Thousand USD | -68.29% |
| 2002 Q1 | 1.6 Million USD | -36.66% |
| 2002 Q2 | 2.34 Million USD | 45.58% |
| 2002 Q3 | 2.21 Million USD | -5.54% |
| 2002 Q4 | 2.69 Million USD | 21.77% |
| 2002 FY | 2.69 Million USD | 6.08% |
| 2001 Q4 | 2.54 Million USD | -48.03% |
| 2001 FY | 2.54 Million USD | -59.06% |
| 2001 Q1 | 2.54 Billion USD | 0.0% |
| 2001 Q3 | 4.89 Million USD | -1.01% |
| 2001 Q2 | 4.94 Million USD | -99.81% |
| 2000 FY | 6.2 Million USD | -22.09% |
| 1999 FY | 7.96 Million USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -273001.739% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -691.471% |
| Evofem Biosciences, Inc. | 72.47 Million USD | -3.379% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -9163.175% |
| Rebus Holdings, Inc. | 5.24 Million USD | -1329.225% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | -26.953% |
| Qrons Inc. | 1.48 Million USD | -4932.535% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -6009.868% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -167521.264% |
| Skye Bioscience, Inc. | 14.07 Million USD | -432.396% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | -40.55% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -681.881% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -17671.747% |
| SQZ Biotechnologies Company | 50.03 Million USD | -49.723% |
| Intellipharmaceutics International Inc. | 12 Million USD | -523.878% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -1845.255% |
| Mesoblast Limited | 188.44 Million USD | 60.243% |
| Marizyme, Inc. | 26.67 Million USD | -180.855% |
| Genus plc | 485 Million USD | 84.553% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -1182.301% |
| Pharming Group N.V. | 244.07 Million USD | 69.304% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -3627.122% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -2877.354% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -1871.579% |
| ContraFect Corporation | 32.53 Million USD | -130.303% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -3681.34% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -1857.338% |
| IMV Inc. | 37.93 Million USD | -97.507% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -536.091% |
| MultiCell Technologies, Inc. | 1617.67 USD | -4631252.501% |
| ONE Bio Corp. | 27.49 Million USD | -172.478% |
| Accustem Sciences Inc. | 1.07 Million USD | -6841.929% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 3.225% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -3442.201% |
| Q BioMed Inc. | 8.13 Million USD | -821.192% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 9.664% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -1355.878% |
| Biomind Labs Inc. | 1.49 Million USD | -4899.293% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 36.895% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -728.56% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -307.098% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -5125.053% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -52625.289% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -37152.133% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -1203.904% |
| GB Sciences, Inc. | 5.41 Million USD | -1282.911% |
| Alpha Cognition Inc. | 7.16 Million USD | -945.672% |
| HST Global, Inc. | 593.59 Thousand USD | -12521.443% |
| CSL Limited | 18.62 Billion USD | 99.598% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -5849.842% |
| Halberd Corporation | 728.71 Thousand USD | -10181.055% |
| Enzolytics Inc. | 365.26 Million USD | 79.489% |
| Agentix Corp. | 2.51 Million USD | -2884.201% |
| Resverlogix Corp. | 67.39 Million USD | -11.164% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -8832.531% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 83.162% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -4271.062% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | -202.756% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -529.416% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -1944.11% |
| AVAX Technologies, Inc. | 3.99 Million USD | -1775.933% |
| Zenith Capital Corp. | 27.56 Thousand USD | -271654.507% |
| Genscript Biotech Corporation | 1.32 Billion USD | 94.349% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -31292.728% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -1906.263% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -10904.151% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -2662.903% |
| Kadimastem Ltd | 3.5 Million USD | -2037.599% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -111839.518% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | -49.053% |
| BioStem Technologies, Inc. | 15.9 Million USD | -371.057% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -16022.264% |
| LadRx Corporation | 2.2 Million USD | -3304.637% |
| Cell Source, Inc. | 15.8 Million USD | -373.976% |
| Regen BioPharma, Inc. | 5.45 Million USD | -1272.761% |
| Regen BioPharma, Inc. | 5.45 Million USD | -1272.761% |
| NovAccess Global Inc. | 7.86 Million USD | -853.092% |
| Affymax, Inc. | 8.87 Million USD | -744.55% |
| Itoco Inc. | 1.65 Million USD | -4431.951% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -3551.846% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -1138.552% |
| Mobile Lads Corp. | 1.31 Million USD | -5603.858% |
| CytoDyn Inc. | 127.89 Million USD | 41.42% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -179138.738% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -4683.012% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -578.298% |
| SYBLEU INC | 681.41 Thousand USD | -10894.801% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -1127.813% |
| International Stem Cell Corporation | 5.27 Million USD | -1319.746% |
| Bioxytran, Inc. | 3.24 Million USD | -2205.585% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -11871.704% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -1522.655% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | -82.75% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | -236.492% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -3599.046% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -1267.652% |
| Neutra Corp. | 973.52 Thousand USD | -7595.713% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -158.211% |
| PureTech Health plc | 125.58 Million USD | 40.342% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -1894.078% |
| IXICO plc | 1.9 Million USD | -3842.552% |
| IntelGenx Technologies Corp. | 20.52 Million USD | -264.947% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 27.49% |
| CSL Limited | 18.62 Billion USD | 99.598% |
| Cellectis S.A. | 249.36 Million USD | 69.956% |